Hainan Huluwa Pharmaceutical Group Co Ltd (605199) - Total Assets
Based on the latest financial reports, Hainan Huluwa Pharmaceutical Group Co Ltd (605199) holds total assets worth CN¥2.56 Billion CNY (≈ $374.03 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 605199 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Hainan Huluwa Pharmaceutical Group Co Ltd - Total Assets Trend (2016–2025)
This chart illustrates how Hainan Huluwa Pharmaceutical Group Co Ltd's total assets have evolved over time, based on quarterly financial data. See Hainan Huluwa Pharmaceutical Group Co Lt book value and equity for net asset value and shareholders' equity analysis.
Hainan Huluwa Pharmaceutical Group Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Hainan Huluwa Pharmaceutical Group Co Ltd's total assets of CN¥2.56 Billion consist of 33.9% current assets and 66.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 3.0% |
| Accounts Receivable | CN¥418.01 Million | 16.1% |
| Inventory | CN¥254.34 Million | 9.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥274.49 Million | 10.6% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Hainan Huluwa Pharmaceutical Group Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Hainan Huluwa Pharmaceutical Group Co Lt (605199) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hainan Huluwa Pharmaceutical Group Co Ltd's current assets represent 33.9% of total assets in 2025, a decrease from 41.1% in 2016.
- Cash Position: Cash and equivalents constituted 3.0% of total assets in 2025, down from 11.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, a decrease from 20.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 16.1% of total assets.
Hainan Huluwa Pharmaceutical Group Co Ltd Competitors by Total Assets
Key competitors of Hainan Huluwa Pharmaceutical Group Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
JW Pharmaceutical Corp
KO:001067
|
Korea | ₩611.56 Billion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Guilin Sanjin Pharmaceutical Co Ltd
SHE:002275
|
China | CN¥4.30 Billion |
|
Fuan Pharmaceutical Group Co
SHE:300194
|
China | CN¥5.97 Billion |
|
DRI Healthcare Trust
TO:DHT-U
|
Canada | $967.26 Million |
|
Hainan Shuangcheng Pharmaceut
SHE:002693
|
China | CN¥816.14 Million |
Hainan Huluwa Pharmaceutical Group Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.63 | 0.84 | 2.22 |
| Quick Ratio | 0.46 | 0.53 | 1.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-510.46 Million | CN¥-232.47 Million | CN¥434.27 Million |
Hainan Huluwa Pharmaceutical Group Co Ltd - Advanced Valuation Insights
This section examines the relationship between Hainan Huluwa Pharmaceutical Group Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.97 |
| Latest Market Cap to Assets Ratio | 0.14 |
| Asset Growth Rate (YoY) | -12.2% |
| Total Assets | CN¥2.60 Billion |
| Market Capitalization | $351.88 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hainan Huluwa Pharmaceutical Group Co Ltd's assets below their book value (0.14x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Hainan Huluwa Pharmaceutical Group Co Ltd's assets decreased by 12.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hainan Huluwa Pharmaceutical Group Co Ltd (2016–2025)
The table below shows the annual total assets of Hainan Huluwa Pharmaceutical Group Co Ltd from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.60 Billion ≈ $380.89 Million |
-12.20% |
| 2024-12-31 | CN¥2.96 Billion ≈ $433.81 Million |
-3.14% |
| 2023-12-31 | CN¥3.06 Billion ≈ $447.85 Million |
+32.37% |
| 2022-12-31 | CN¥2.31 Billion ≈ $338.33 Million |
+31.30% |
| 2021-12-31 | CN¥1.76 Billion ≈ $257.68 Million |
+15.76% |
| 2020-12-31 | CN¥1.52 Billion ≈ $222.59 Million |
+39.99% |
| 2019-12-31 | CN¥1.09 Billion ≈ $159.00 Million |
-0.49% |
| 2018-12-31 | CN¥1.09 Billion ≈ $159.79 Million |
+35.28% |
| 2017-12-31 | CN¥807.21 Million ≈ $118.12 Million |
+50.61% |
| 2016-12-31 | CN¥535.95 Million ≈ $78.43 Million |
-- |
About Hainan Huluwa Pharmaceutical Group Co Ltd
Hainan Huluwa Pharmaceutical Group Co., Ltd. research, develops, produces, and sells drugs in the areas of Children's digestive system, respiratory system, anti-infection, anti-virus and other fields in China. The company offers pediatrics, gynecology, antibiotics, respiratory, digestive system, cardiovascular and cerebrovascular, nourishment, and other medicine products. Hainan Huluwa Pharmaceut… Read more